by Sekisui Diagnostics
There are certain milestones in life that no one looks forward to—having your wisdom teeth pulled. That first mammogram! At the top of the list for men is likely that first rectal exam at 40 or 50 as an initial screening for prostate cancer. But, like those pesky wisdom teeth and the oh-so-important mammogram, screening for prostate cancer is important and necessary.
A policy paper produced by the European Association of Urology1 states that there were approximately 450,000 cases of prostate cancer in Europe in 2018 and 107,000 deaths expected. In 2019, the American Cancer Society estimates2 that there will be about 174,650 new cases of prostate cancer in the U.S. Globally prostate cancer3 is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall.
That being said, prostate cancer often can be treated successfully. In fact, the localized and regional five-year survival rates4 for this type of cancer are near 100%! As with all cancers, early diagnosis is important. Most prostate cancers are first found5 during screening with a prostate-specific antigen (PSA) blood test or a digital rectal exam (DRE). While prostate cancers usually don’t cause symptoms in the early stages, more advanced cancers are sometimes first found because of symptoms they cause.
So why are there ongoing controversial discussions about PSA screening? Why do the United States and Europe hold different positions regarding some aspects of screening?
So What’s the Deal?
How can one argue that it’s better not to screen for a cancer? The medical community is divided due to the risk of overdiagnosis and overtreatment. Cancer overdiagnosis6 is the detection of cancer that would not develop any symptoms during a man’s lifetime if not identified by early detection or not result in cancer-related death. Overtreatment refers to unnecessary medical interventions, including extensive treatment for a condition that requires only limited treatment.
According to the European Association of Urology1, the risk of overdiagnosis has been estimated to be as high as 40% in screen-detected prostate cancer, leading to unnecessary biopsies and detection of insignificant cancers, which could lead to overtreatment. In 2012, the U.S. Preventive Services Task Force (USPSTF) actually recommended against7 screening for prostate cancer in all men! However in 2017, the USPSTF released a new draft recommendation for prostate cancer screening encouraging providers7 to inform men ages 55 to 69 about the benefits and harms of prostate cancer screening.
Practitioners in both the UK and the U.S.1 were advised not to perform PSA for early detection. Two independent studies performed in 2017 and 2018 found that a lack of prostate cancer screening may be reversing1 the trend of declining death rates—meaning mortality from these type of cancer could be on the rise. This year, the European Association of Urology made a call to action8, stating, “Urgent action is required to ensure the new Commission is mandated to support EU Member States in prostate cancer screening in their national cancer plans.”
EAU Policy Coordinator Michelle Battye wants the 2003 Council Recommendations on population-based screening to be “urgently reviewed,” with prostate cancer added to the list of cancers to be addressed, and wants member states to bring good practice on prostate cancer screening to the Steering Group on Health Promotion, Disease Prevention and Management of non-communicable diseases.
How the U.S. Responded
As we briefly mentioned above, in 2017 the USPSTF released new recommendation for prostate cancer screening encouraging providers7 to inform men ages 55 to 69 about the benefits and harms of prostate cancer screening. The American Cancer Society recommends9 that men learn as much as they can about prostate cancer screening risks and benefits and discuss the information with their doctor before deciding whether to be tested. Men at average risk of prostate cancer should have this discussion at age 50. Men at higher than average risk should have the discussion starting at age 40 or 45.
The consequences of decreased PSA screening10 are numerous:
- Increased mortality
- The effects of non-curative intervention
- Psychological complications of recurrent prostate cancer
So do the risks of prostate cancer screening outweigh the benefits? That’s not a question any man should answer alone—he should discuss the pros and cons of screening with his doctor to make an informed decision. However, physicians should bring this topic to the table at the appropriate time for all affected patients.
In the end, prostate cancer screening is important, as it is with all types of available cancer screenings. A little bit of research can inundate you with statistics, recommendations, and lots of other frightening material. What matters is that physicians are aware of recommended guidelines and available screening and treatment options, and that patients are given the information they need to make informed decisions regarding their health.
Sekisui Diagnostics offers two tests (please note that only one is currently available in the U.S.). The FastPack® IP Total PSA immunoassay11 is a chemiluminescent immunoassay for the in-vitro quantitative determination of PSA in human serum and plasma as an aid in the management of patients with prostate cancer. It offers results in 12 minutes.
The FastPack® IP Free PSA Immunoassay12, not currently available in the U.S., is a chemiluminescent immunoassay for the in-vitro quantitative determination of free prostate-specific antigen (free PSA) in human serum. It is designed for use in conjunction with the FastPack IP System for calculating the ratio of free/total PSA, expressed as a percentage (percent free PSA). A free PSA test13 can be used instead of a biopsy if PSA levels are slightly elevated, and may be used to determine how aggressive a recurring cancer is.